act now flow better - wmc medical · hemothorax *references available upon request. acute 9-12%...
TRANSCRIPT
EU Authorized Representative:
Emergo Europe
Molenstraat 15
2513 BH, The Hague
The Netherlands
Manufactured For:
ClearFlow, Inc.
1630 S. Sunkist St., Suite E
Anaheim, CA, US, 92806
ML004-IMCV00031391 REVA
Copyright © 2014 ClearFlow, Inc. All Rights Reserved.
™ Trademarks and ® Registered Trademarks of ClearFlow, Inc.
US Patents 7,854,728, 7,951,243, 8,048,233, 8,246,752, 8,388,759,
8,702,662, and 8,951,355. International Patents AU 2004235782;
CA 2,565,303. Other US and international patents pending.
US FDA 510(k): K093565; Health Canada License Number 82994;
ARTG Identifier 218317
1 Karimov, J.H., Gillinov, A.M., Schenck, L., et al. Incidence of chest tube clogging after cardiac surgery:
a single-centre prospective observational study. Eur J Cardiothorac Surg. 2013;44(6):1029-1036.
doi:10.1093/ejcts/ezt140.
2 Shiose, A., Takaseya, T., Fumoto, H., et al. Improved drainage with active chest tube clearance.
Interact CardioVasc Thorac Surg. 2010;10:685-688. doi: 10.1510/icvts.2009.229393.
3 Dixon, B., Santamaria, J.D., Reid, D., et al. The association of blood transfusion with mortality after
cardiac surgery: cause or confounding? Transfusion. 2013;53(1):19-27. doi:
10.1111/j.1537-2995.2012.03697.x.
4 2010 Nationwide Inpatient Sample (NIS), from the DHHS Agency for Healthcare Research and Quality
(AHRQ) Healthcare Cost and Utilization Project (HCUP). Data extracted using ICD-9 codes from over
313,000 US adult heart surgery patients. Analysis performed by Fletcher Spaght, Inc.
5 Arakawa, Y., Shiose, A., Takaseya, T. et al. Superior Chest Drainage With an Active Tube Clearance
System: Evaluation of a Downsized Chest Tube. Ann Thorac Surg. 2011;91:580-583. doi:
10.1016/j.athoracsur.2010.10.018.
References
ACT NOWImprove Outcomes, Lower Costs
Learn more about the innovative new
technology of PleuraFlow® Active
Clearance Technology® (ACT™).
Contact your local representative:
*PleuraFlow ACT System includes a straight silicone chest tube
and clearance apparatus.
CODE DESCRIPTION
20FR PleuraFlow® ACT™ System*
24FR PleuraFlow® ACT™ System*
28FR PleuraFlow® ACT™ System*
32FR PleuraFlow® ACT™ System*
Ordering Information
PF-20
PF-24
PF-28
PF-32
www.clearflow.com
FLOW BETTERWITH PLEURAFLOW® ACTIVE CLEARANCE TECHNOLOGY®
DON’T LET RETAINED BLOOD SYNDROME BLOCK YOUR PATIENT’S RECOVERY
More than 36% of
patients suffer from
blocked chest tubes.
Blocked chest
tubes can lead to
Retained Blood Syndrome in
your patients.
Retained Blood Syndrome (RBS) causes multiple
mechanical and inflammatory complications that may lead
to additional interventions and readmissions.2,3
A recent prospective study found that of these failures,
86% are intra-thoracic and invisible to bedside caregivers1.
The crucial hours post-surgery, when the patient is still
bleeding, are vitally important. Why risk patient outcomes
on a conventional chest tube to evacuate blood from the
surgical site?
Patient outcomes
and healthcare costs
are seriously
impacted by RBS.
hours days weeks months years
3-6%pericardial tamponade,hemothorax
*References available upon request.
ACUTE
9-12%bloody pleural (9-12%) and pericardial (2%) effusions
SUB-ACUTE
2-3%constrictive pericarditis, fibrothorax
CHRONIC
Improve Patient Safety
By eliminating accumulated blood and
fluid at the surgical site, you reduce
risky and unwanted complications.
Plus, you will never again have to break
sterility in order to clear a clogged tube.
Minimize Patient Discomfort
Our 20FR PleuraFlow removes nearly triple
the amount of blood than a traditional
32FR drain5 (525 ml vs. 183 ml) and your
patients will benefit from a smaller and
more flexible silicone tube.
Reduce Hospital Costs
The average cost to treat a patient
with one or more RBS complications
that require a re-operation or
intervention is $28,814.4
COST OF CARE
16-23% combined
Complications Requiring Intervention*
LENGTH OF STAY MORTALITY RATE
Unreimbursable Costs Per Patient with RBS4
$28,814per RBS
5.8 days doubledIncrease 3% to 6%
INCREASE55% 2x2x
Clearance Loop enables
proactive clearance of
thrombus obstruction from
the chest tube and provides
real-time patency feedback.
BLOCKED TUBES LEAD TO COMPLICATIONS
KEEP CHEST TUBES CLEARwith PleuraFlow® Active Clearance Technology® (ACT™)
Developed by cardiac surgeons, PleuraFlow ACT is a unique system that
proactively clears chest tubes and prevents the retention of blood in
the chest cavity. ACT technology is used to maintain tube patency and
clears the pathway to a successful recovery before and after discharge.
More than 36% of
patients suffer from
blocked chest tubes.
Blocked chest
tubes can lead to
Retained Blood Syndrome in
your patients.
Retained Blood Syndrome (RBS) causes multiple
mechanical and inflammatory complications that may lead
to additional interventions and readmissions.2,3
A recent prospective study found that of these failures,
86% are intra-thoracic and invisible to bedside caregivers1.
The crucial hours post-surgery, when the patient is still
bleeding, are vitally important. Why risk patient outcomes
on a conventional chest tube to evacuate blood from the
surgical site?
Patient outcomes
and healthcare costs
are seriously
impacted by RBS.
hours days weeks months years
3-6%pericardial tamponade,hemothorax
*References available upon request.
ACUTE
9-12%bloody pleural (9-12%) and pericardial (2%) effusions
SUB-ACUTE
2-3%constrictive pericarditis, fibrothorax
CHRONIC
Improve Patient Safety
By eliminating accumulated blood and
fluid at the surgical site, you reduce
risky and unwanted complications.
Plus, you will never again have to break
sterility in order to clear a clogged tube.
Minimize Patient Discomfort
Our 20FR PleuraFlow removes nearly triple
the amount of blood than a traditional
32FR drain5 (525 ml vs. 183 ml) and your
patients will benefit from a smaller and
more flexible silicone tube.
Reduce Hospital Costs
The average cost to treat a patient
with one or more RBS complications
that require a re-operation or
intervention is $28,814.4
COST OF CARE
16-23% combined
Complications Requiring Intervention*
LENGTH OF STAY MORTALITY RATE
Unreimbursable Costs Per Patient with RBS4
$28,814per RBS
5.8 days doubledIncrease 3% to 6%
INCREASE55% 2x2x
Clearance Loop enables
proactive clearance of
thrombus obstruction from
the chest tube and provides
real-time patency feedback.
BLOCKED TUBES LEAD TO COMPLICATIONS
KEEP CHEST TUBES CLEARwith PleuraFlow® Active Clearance Technology® (ACT™)
Developed by cardiac surgeons, PleuraFlow ACT is a unique system that
proactively clears chest tubes and prevents the retention of blood in
the chest cavity. ACT technology is used to maintain tube patency and
clears the pathway to a successful recovery before and after discharge.
EU Authorized Representative:
Emergo Europe
Molenstraat 15
2513 BH, The Hague
The Netherlands
Manufactured For:
ClearFlow, Inc.
1630 S. Sunkist St., Suite E
Anaheim, CA, US, 92806
ML004-IMCV00031391 REVA
Copyright © 2014 ClearFlow, Inc. All Rights Reserved.
™ Trademarks and ® Registered Trademarks of ClearFlow, Inc.
US Patents 7,854,728, 7,951,243, 8,048,233, 8,246,752, 8,388,759,
8,702,662, and 8,951,355. International Patents AU 2004235782;
CA 2,565,303. Other US and international patents pending.
US FDA 510(k): K093565; Health Canada License Number 82994;
ARTG Identifier 218317
1 Karimov, J.H., Gillinov, A.M., Schenck, L., et al. Incidence of chest tube clogging after cardiac surgery:
a single-centre prospective observational study. Eur J Cardiothorac Surg. 2013;44(6):1029-1036.
doi:10.1093/ejcts/ezt140.
2 Shiose, A., Takaseya, T., Fumoto, H., et al. Improved drainage with active chest tube clearance.
Interact CardioVasc Thorac Surg. 2010;10:685-688. doi: 10.1510/icvts.2009.229393.
3 Dixon, B., Santamaria, J.D., Reid, D., et al. The association of blood transfusion with mortality after
cardiac surgery: cause or confounding? Transfusion. 2013;53(1):19-27. doi:
10.1111/j.1537-2995.2012.03697.x.
4 2010 Nationwide Inpatient Sample (NIS), from the DHHS Agency for Healthcare Research and Quality
(AHRQ) Healthcare Cost and Utilization Project (HCUP). Data extracted using ICD-9 codes from over
313,000 US adult heart surgery patients. Analysis performed by Fletcher Spaght, Inc.
5 Arakawa, Y., Shiose, A., Takaseya, T. et al. Superior Chest Drainage With an Active Tube Clearance
System: Evaluation of a Downsized Chest Tube. Ann Thorac Surg. 2011;91:580-583. doi:
10.1016/j.athoracsur.2010.10.018.
References
ACT NOWImprove Outcomes, Lower Costs
Learn more about the innovative new
technology of PleuraFlow® Active
Clearance Technology® (ACT™).
Contact your local representative:
*PleuraFlow ACT System includes a straight silicone chest tube
and clearance apparatus.
CODE DESCRIPTION
20FR PleuraFlow® ACT™ System*
24FR PleuraFlow® ACT™ System*
28FR PleuraFlow® ACT™ System*
32FR PleuraFlow® ACT™ System*
Ordering Information
PF-20
PF-24
PF-28
PF-32
www.clearflow.com
FLOW BETTERWITH PLEURAFLOW® ACTIVE CLEARANCE TECHNOLOGY®
DON’T LET RETAINED BLOOD SYNDROME BLOCK YOUR PATIENT’S RECOVERY